A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms, Germ Cell and Embryonal
  • Pyrrolidinones
  • Quinolines

abstract

  • Tivantinib was well tolerated but did not demonstrate single-agent activity in patients with relapsed/refractory GCTs. Rapid accrual to this phase 2 trial was achieved in this rare patient population through multicenter collaboration.

publication date

  • August 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s10637-013-9934-y

PubMed ID

  • 23417696

Additional Document Info

start page

  • 1016

end page

  • 22

volume

  • 31

number

  • 4